Jacobson Pharma Corporation Limited (2633) AI Stock Analysis

• Market Cap: HK$2.77B
• Dividend Yield: 4.14%
• Average Volume (3M): 756.42K
• Price to Earnings (P/E): 9.6
• Beta (1Y): 0.16
• Revenue Growth: 7.43%
• EPS Growth: 21.88%
• Country: HK
• Employees: 1,730
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.08
• Shares Outstanding: 2,000,221,000
• 10 Day Avg. Volume: 770,200
• 30 Day Avg. Volume: 756,422
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$1.50
• Price Target Upside: 2.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 71 Outperform
• Price Target: HK$1.50 ▲(2.74% Upside)

Jacobson Pharma Corporation Limited's overall stock score is driven by its strong financial performance and attractive valuation. The company's solid profitability and effective cash management are significant strengths. The valuation metrics, including a low P/E ratio and high dividend yield, enhance its appeal. However, mixed technical indicators suggest some caution in the short term. The absence of recent earnings call insights or notable corporate events means these factors do not influence the score.

Jacobson Pharma Corporation Limited Business Overview & Revenue Model

Company Description

Jacobson Pharma Corporation Limited, through its subsidiaries, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including the respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergics, scar treatment, oral anti-diabetics, and anti-infective, as well as arsenic trioxide oral solutions, rosuvastatin tablets, and atorvastatin tablets. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines, such as Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablets. In addition, it engages in the trading of medical supplies; procurement of packaging materials; sale of healthcare and herbal products; research and development; and property holding activities. Jacobson Pharma Corporation Limited sells its products to hospitals and clinics, and registered pharmacies, as well as to doctors in private and retail outlets, and trading companies. The company was incorporated in 2016 and is headquartered in Kwun Tong, Hong Kong. Jacobson Pharma Corporation Limited is a subsidiary of Kingshill Development Limited.

How the Company Makes Money

Jacobson Pharma Corporation Limited primarily generates revenue through the sale of its generic drugs and proprietary medicines. The company benefits from a broad portfolio of over-the-counter and prescription medications, which are distributed through a well-established network of healthcare institutions, pharmacies, and retail outlets. Additionally, the company engages in strategic partnerships and alliances to enhance its product offerings and expand market reach. Jacobson Pharma also places significant emphasis on research and development to innovate and introduce new products, thus ensuring sustained revenue growth. Furthermore, the company's expansion into health supplements and its efforts to penetrate international markets contribute to its diversified revenue streams.

Jacobson Pharma Corporation Limited Financial Statement Overview

Summary

Jacobson Pharma Corporation Limited exhibits solid financial performance across its income statement, balance sheet, and cash flow statement. The company demonstrates strong profitability, efficient operations, and effective cash management. While growth trends are generally positive, attention to revenue fluctuations and debt levels will be crucial for sustaining long-term growth and stability.

Income Statement

Jacobson Pharma Corporation Limited has demonstrated a strong performance in its income statement. The gross profit margin is healthy, indicating effective cost management. The net profit margin reflects profitability, with consistent growth in net income over the years. Revenue growth has been positive, though there was a slight decline in the most recent year. EBIT and EBITDA margins are solid, showing operational efficiency. Overall, the company maintains a robust financial health in its income statement metrics.

Balance Sheet

The balance sheet of Jacobson Pharma indicates a stable financial position with a solid equity base. The debt-to-equity ratio suggests a moderate level of leverage, manageable within industry norms. Return on Equity (ROE) is favorable, showing effective use of equity capital to generate profits. The equity ratio is strong, signifying a substantial proportion of assets financed by shareholders' equity. However, the company should monitor its debt levels to ensure long-term financial flexibility.

Cash Flow

Cash flow analysis reveals a strong operating cash flow, indicating excellent cash generation capability. The free cash flow has grown consistently, supporting reinvestment opportunities and shareholder returns. Ratios of operating and free cash flow to net income demonstrate effective cash management. The company has improved its free cash flow generation, although capital expenditures have seen fluctuations. Overall, the cash flow statement highlights robust cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.56B	1.58B	1.47B	1.79B	1.60B	1.45B
Gross Profit	670.87M	692.94M	620.48M	747.17M	620.52M	534.15M
EBITDA	503.26M	558.87M	489.81M	462.04M	415.49M	377.20M
Net Income	253.22M	300.83M	266.97M	251.04M	177.67M	173.71M
Balance Sheet
Total Assets	3.61B	3.65B	3.49B	5.38B	4.76B	4.87B
Cash, Cash Equivalents and Short-Term Investments	563.79M	509.05M	411.94M	1.04B	478.65M	480.35M
Total Debt	699.85M	773.21M	749.38M	1.60B	1.41B	1.65B
Total Liabilities	1.15B	1.17B	1.09B	2.12B	1.80B	2.01B
Stockholders Equity	2.43B	2.45B	2.37B	2.74B	2.49B	2.39B
Cash Flow
Free Cash Flow	429.97M	278.39M	354.85M	585.23M	345.89M	347.99M
Operating Cash Flow	495.44M	526.78M	484.36M	648.24M	409.76M	411.35M
Investing Cash Flow	-217.31M	-297.76M	43.34M	-44.09M	-52.75M	-375.40M
Financing Cash Flow	-733.81M	-131.30M	-1.05B	-45.64M	-357.89M	21.36M

Jacobson Pharma Corporation Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.46
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2633, the sentiment is Negative. The current price of 1.46 is below the 20-day moving average (MA) of 1.47, below the 50-day MA of 1.50, and above the 200-day MA of 1.22, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.60 is Neutral, neither overbought nor oversold. The STOCH value of 41.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2633.

Jacobson Pharma Corporation Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2161	81 Outperform	2.54B	12.83	18.23%	6.81%	20.65%	63.21%
2877	74 Outperform	6.38B	7.16	11.25%	5.98%	-20.64%	-25.39%
2348	73 Outperform	1.82B	9.55	0.00%	5.21%	2.89%	-68.83%
6896	72 Outperform	2.56B	8.82	21.73%	14.45%	-2.70%	2.19%
2633	71 Outperform	HK$2.77B	9.64	12.47%	4.14%	7.43%	21.88%
0950	66 Neutral	1.46B	14.93	5.64%	1.90%	19.80%	55.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Jacobson Pharma Corporation Limited Corporate Events

Jacobson Pharma Announces AGM Results and Strategic Appointments

Jacobson Pharma Corporation Limited announced the results of its Annual General Meeting held on July 28, 2025, where all proposed resolutions were passed. Key outcomes include the approval of final and special dividends, re-election of directors, and the appointment of a new independent non-executive director. These decisions reflect the company’s strategic direction and commitment to shareholder value, potentially impacting its market position and stakeholder confidence.

Jacobson Pharma Announces Board Composition and Governance Structure

Jacobson Pharma Corporation Limited announced the composition and roles of its board of directors and board committees, highlighting the leadership of Mr. Sum Kwong Yip, Derek as Chairman, CEO, and Executive Director. The announcement underscores the company’s governance structure, which includes committees focused on audit, remuneration, nomination, executive, and environmental, social, and governance matters, reflecting its commitment to comprehensive corporate governance.

Jacobson Pharma Updates Nomination Committee Terms to Boost Diversity and Governance

Jacobson Pharma Corporation Limited has revised the terms of reference for its Nomination Committee, which plays a crucial role in identifying and evaluating candidates for the board of directors, as well as overseeing policies related to board and workforce diversity. The updated terms emphasize the importance of independent non-executive directors and gender diversity within the committee. This move is expected to enhance the governance and diversity of the company’s leadership, potentially improving its strategic decision-making and aligning with broader industry trends towards inclusivity.

Jacobson Pharma Announces Key Dates for AGM and Dividends

Jacobson Pharma Corporation Limited has announced key dates for its upcoming Annual General Meeting and proposed dividends. The company has set the record date for shareholders to attend and vote at the meeting on July 28, 2025, with the register of members closed from July 22 to July 28, 2025. Additionally, the record date for entitlement to the proposed final and special dividends is set for August 14, 2025, with the register closed from August 13 to August 14, 2025. These announcements are crucial for shareholders as they outline the timeline for participation in corporate governance and potential financial benefits.

Jacobson Pharma Announces Virtual AGM and Dividend Plans

Jacobson Pharma Corporation Limited has announced its upcoming annual general meeting to be held virtually on July 28, 2025. Key agenda items include the approval of financial statements, declaration of final and special dividends, re-election of directors, and the reappointment of KPMG as auditor. Additionally, the company seeks shareholder approval for a mandate to repurchase up to 10% of its issued shares, which could impact the company’s stock liquidity and shareholder value.